Table 2.
Selected triplet treatment regimens for transplant ineligible newly diagnosed multiple myeloma.
| Clinical trial | Number of patients | Treatment regimen | Median age (years) | Median follow up (months) | Progression-free survival (months) | Overall survival (months) |
|---|---|---|---|---|---|---|
| ELOQUENT-171 | 748 | Elotuzumab + Rd vs Rd | 73 | 65 | 31.4 vs 29.5 | NR for both groups |
| TOURMALINE-MM272 | 705 | IRd vs Rd | 73 vs 74 | 55 | 35.3 vs 21.8 | NR vs 51.8 |
| MAIA69 | 737 | DRd vs Rd | 73 vs 74 | 56 | NR vs 34.4 | NR in both groups |
| ENDURANCE60 | 1087 | VRd vs KRd | 65 | 9 | 34.4 vs 34.6 | NR in both groups |
| SWOG-S077748,49 | 525 | VRD vs Rd | 63 | 84 | 41 vs 29 | NR vs 69 |
Abbreviations: Rd, lenalidomide, dexamethasone; IRd, ixazomib, lenalidomide, dexamethasone; DRd, daratumumab, lenalidomide, dexamethasone; VRd, bortezomib, lenalidomide, dexamethasone; KRd, carfilzomib, lenalidomide, dexamethasone; NR, not reached.